



Joelle Woolston  
Intralytix, Inc.  
8681 Robert Fulton Drive  
Columbia, MD 21046

Re: GRAS Notice No. GRN 000834

Dear Ms. Woolston:

The Food and Drug Administration (FDA, we) completed our evaluation of Intralytix, Inc.'s (Intralytix) supplement to GRN 000834. We received the supplement on April 17, 2023. The supplement addresses additional uses for the subject of GRN 000834. Intralytix submitted clarifying information on August 14, 2023, which included clarification regarding the specifications, results from three non-consecutive batch analyses, a revised dietary exposure assessment, and an explanation of the provided efficacy studies.

We previously responded to GRN 000834 on November 8, 2019. We stated that we had no questions at that time regarding Intralytix's conclusion that three to eight<sup>1</sup> bacteriophages (phage) specific to Shiga toxin-producing *Escherichia coli* (STEC; *E. coli* phage preparation) is GRAS for use as antimicrobial treatments on meat, poultry, fruits, vegetables, dairy products (including cheese), fish, and other seafood at a level of no greater than  $10^8$  plaque-forming units (PFU)/g of food.

In the supplement dated April 17, 2023, Intralytix informs us of its view that *E. coli* phage preparation is GRAS, through scientific procedures, for use as an antimicrobial at up to  $10^8$  PFU/g of food in grain and grain products.

Intralytix states that the identity, the method of manufacture, and the specifications are the same as discussed in GRN 000834. Intralytix estimates the dietary exposure to *E. coli* phage preparation based on the intended maximum use level of  $1 \times 10^8$  PFU/g of food and the average per capita daily consumption of all foods in which *E. coli* phage preparation could be used, estimated using data from the Food Availability (Per Capita) Data System (Economic Research Service, U.S. Department of Agriculture. Intralytix estimates the dietary exposure to *E. coli* phage preparation from all uses of *E. coli* phage preparation to be 78.3  $\mu\text{g}/\text{person}/\text{d}$ .

---

<sup>1</sup> Intralytix intends to produce *E. coli* phage preparations containing a mixture of three to eight double-stranded DNA lytic phages specific to STEC, and subject to the same manufacturing and safety standards in GRN 000834.

Intralytix conducted a literature review through April 2023 and concludes that the safety of bacteriophage continues to be confirmed and that there is an absence of adverse effects. To support use in grain and grain products, Intralytix's supplement includes supporting data examining the efficacy of *E. coli* phage preparation in wheat grain as well as wheat grain subjected to the milling process in a commercial milling facility.

Based on the data and information presented in the supplement, Intralytix concludes that *E. coli* phage preparation is GRAS for its intended use.

### **Standards of Identity**

In the supplement, Intralytix states its intention to use *E. coli* phage preparation in several food categories, including foods for which standards of identity exist, located in Title 21 of the CFR. We note that an ingredient that is lawfully added to food products may be used in a standardized food only if it is permitted by the applicable standard of identity.

### **Allergen Labeling**

The Federal Food, Drug, and Cosmetic Act (FD&C Act) requires that the label of a food that is or contains an ingredient that contains a "major food allergen" declare the allergen's presence (section 403(w)). The FD&C Act defines a "major food allergen" as one of nine foods or food groups (i.e., milk, eggs, fish, Crustacean shellfish, tree nuts, peanuts, wheat, soybeans, and sesame) or a food ingredient that contains protein derived from one of those foods. *E. coli* phage preparation may require labeling under the FD&C Act because it may contain protein derived from soy. Questions about petitions or notifications for exemptions from the food allergen labeling requirements should be directed to the Division of Food Ingredients in the Office of Food Additive Safety. Questions related to food labeling in general should be directed to the Office of Nutrition and Food Labeling in the Center for Food Safety and Applied Nutrition.

### **Section 301(ll) of the FD&C Act**

Section 301(ll) of the FD&C Act prohibits the introduction or delivery for introduction into interstate commerce of any food that contains a drug approved under section 505 of the FD&C Act, a biological product licensed under section 351 of the Public Health Service Act, or a drug or a biological product for which substantial clinical investigations have been instituted and their existence made public, unless one of the exemptions in section 301(ll)(1)-(4) applies. In our evaluation of Intralytix's supplement concluding that *E. coli* phage preparation is GRAS under its intended conditions of use, we did not consider whether section 301(ll) or any of its exemptions apply to foods containing *E. coli* phage preparation. Accordingly, our response should not be construed to be a statement that foods containing *E. coli* phage preparation, if introduced or delivered for introduction into interstate commerce, would not violate section 301(ll).

## Conclusions

Based on the information that Intralytix provided, as well as other information available to FDA, we have no questions at this time regarding Intralytix's conclusion that *E. coli* phage preparation is GRAS under its intended conditions of use. This letter is not an affirmation that *E. coli* phage preparation is GRAS under 21 CFR 170.35. Unless noted above, our review did not address other provisions of the FD&C Act. Food ingredient manufacturers and food producers are responsible for ensuring that marketed products are safe and compliant with all applicable legal and regulatory requirements.

In accordance with 21 CFR 170.275(b)(2), the text of this letter responding to the supplement to GRN 000834 is accessible to the public at [www.fda.gov/grasnoticeinventory](http://www.fda.gov/grasnoticeinventory).

Sincerely,

Susan J.  
Carlson -S

Digitally signed by Susan J.  
Carlson -S  
Date: 2024.01.12 16:30:18  
-05'00'

Susan J. Carlson, Ph.D.  
Director  
Division of Food Ingredients  
Office of Food Additive Safety  
Center for Food Safety  
and Applied Nutrition